SAMe 400

SAMe 400

Jarrow Formulas4.5 (3,092 ratings)
Format:Tablet Quantity: 30 Tablet(s) · 30 servings
Goals
$24.00 $0.80 per serving
Daily VitaLowest$24.00Amazon$31.47Daily Vita$38.99iHerb$44.96Vitacost$44.96iHerb$44.96Vitacost$44.96

About this product

A one-tablet serving delivers a full SAMe amount for mood, joint, stress, and methylation use. The focused formula is easy to understand.

No stabilizing salt or acid-resistant coating is identified. The label also does not clarify net active SAMe or sealed packaging.

Competitive cost is appealing, but a lower price cannot fully offset delivery uncertainty. A stabilized enteric product is the stronger choice.

Who is it for
  • Adults seeking full-dose SAMe
  • Price-conscious tablet users
  • People targeting mood or joint support
Best for
  • Full-strength one-tablet use
  • Focused SAMe supplementation
  • Multi-goal routines

Pros

  • Full commonly used amount
  • One-tablet serving
  • Single active ingredient
  • Competitive cost

Cons

  • Salt form is unspecified
  • No enteric coating
  • Moisture packaging is unclear
  • Net active yield is not separated

Warnings

  • SAMe may induce mania in bipolar disorder
  • Do not combine with serotonergic antidepressants, MAO inhibitors, or triptans without oversight
  • SAMe can cause anxiety, insomnia, nausea, or diarrhea

Product analysis

76 out of 100
Full-dose convenience and decent value are weakened by no stated stabilization or gastric protection.

AI assessment of the formula, label and price. How scoring works

Nutrient quality84

Neither a stabilized salt nor acid-resistant delivery is identified. A full commonly used amount provides strong active depth, although net SAMe yield remains unclear.

Ingredient transparency79

The active amount is disclosed without a hidden blend. Missing net active yield, complete directions, and non-active ingredients leave important gaps.

Customer satisfaction69

The supplied average rating is strong and the rating volume is substantial. No specific experience details were provided to judge repeated complaints or purpose alignment.

Value for money70

Delivery limitations or high cost weaken practical value. It remains moderately competitive but does not clearly lead the category.

Format
Tablet
Container
30 Tablet(s)
Per serving
$0.80
Also available
SAMe 200SAMe 200 mg • 60 Tablet(s) • 60 servings$15.00
Customer rating
4.5 · 3,092 ratings
Report analysis

Goals

Joint Health
Joint Health
Impact
High effect
B- Ingredient FitF PathwaysB+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may ease symptoms of osteoarthritis, but the benefit is uncertain. Any improvement concerns how a joint feels and functions, rather than repair of damaged cartilage or prevention of future problems. The active ingredient is identified here, although the salt name alone doesn't verify the coating, stability or absorption needed to know how closely this preparation matches others.

How this product is rated for Joint Health

Ingredient fit75

SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Goal fit
SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Dose adequacy
The serving provides 400 mg active SAMe, below the 800 mg comparison anchor; salt mass is not extra active SAMe.

Pathways15

SAMe relates mainly to the cartilage matrix, the material that gives cartilage its structure; symptom relief does not mean cartilage repair.
Depth
SAMe relates mainly to the cartilage matrix, the material that gives cartilage its structure; symptom relief does not mean cartilage repair.
Breadth
The main connection concerns cartilage structure, with a smaller connection to inflammation; this does not imply broad joint protection.

Evidence81

SAMe may ease osteoarthritis symptoms, but the benefit is uncertain. The active SAMe amount does not verify its coating, stability or absorption.
Evidence strength
SAMe may ease osteoarthritis symptoms, but the benefit is uncertain.
Studied preparation
The active SAMe amount does not verify its coating, stability or absorption.

Formulation logic100

SAMe has no missing required partner here, and no particular ingredient conflict is identified.
Partner coverage
SAMe does not require another ingredient for its individual role here.
Conflicts
No particular ingredient conflict is identified.
Effective doses
The serving provides 400 mg active SAMe, below the 800 mg comparison anchor; salt mass is not extra active SAMe.
Study evidence
SAMe Supportive 9 studies
Detoxification
Detoxification
Impact
Highest effect
A Ingredient FitC- PathwaysA- EvidenceA+ Formulation Logic
SAMe · 400 mg

Whether SAMe helps your body remove toxins in everyday use is unclear. Its connection with liver disease doesn't provide a reliable expectation for a routine cleanse. The declared SAMe amount is separate from the mass of its source salt, and a larger serving doesn't by itself show a greater detoxification benefit.

How this product is rated for Detoxification

Ingredient fit95

SAMe is the relevant ingredient, but its routine toxin-removal benefit remains unclear. A serving supplies 400 mg SAMe, compared with the 400 mg reference amount; this comparison isn't a detoxification dosing recommendation.
Goal fit
SAMe is the relevant ingredient, but its routine toxin-removal benefit remains unclear.
Dose adequacy
A serving supplies 400 mg SAMe, compared with the 400 mg reference amount; this comparison isn't a detoxification dosing recommendation.

Pathways59

The connection concerns methyl-group supply, a chemical processing role rather than proof of toxin removal.
Depth
The connection concerns methyl-group supply, a chemical processing role rather than proof of toxin removal.
Breadth
The relevant connection is narrow; no additional broad toxin-removal effect follows from it.

Evidence86

Liver-disease outcomes do not provide a reliable expectation of routine toxin removal from this SAMe serving.
Evidence strength
Liver-disease outcomes do not provide a reliable expectation of routine toxin removal from this SAMe serving.
Studied preparation
This SAMe preparation cannot be assumed to reproduce liver-disease outcomes in everyday use.

Formulation logic100

No particular ingredient conflict is identified. The relevant ingredient roles do not require an additional partner here.
Partner coverage
No additional partner is required for the relevant ingredient roles.
Conflicts
No particular ingredient conflict is identified.
Effective doses
A serving supplies 400 mg SAMe, compared with the 400 mg reference amount; this comparison isn't a detoxification dosing recommendation.
Study evidence
SAMe Supportive 30 studies
Mood Support
Mood Support
Impact
Moderate effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe may help with depressive symptoms in some treatment settings, but whether it improves everyday mood in generally healthy adults is unclear. Its connection to mood comes from contexts involving diagnosed depression and, sometimes, concurrent treatment. That makes it difficult to predict a benefit from taking this serving on its own.

How this product is rated for Mood Support

Ingredient fit75

SAMe is the relevant ingredient for mood, with no additional unrelated actives identified. Amounts differ in how closely they match the ingredient comparisons.
Goal fit
The relevant ingredients connect directly or conditionally to mood, without additional unrelated actives.
Dose adequacy
SAMe: 400 mg per serving. These are ingredient comparisons, not guarantees of a mood benefit.

Pathways11

The ingredients relate mainly to mood-related nerve signalling; that role alone does not predict a benefit.
Depth
The ingredients relate mainly to mood-related nerve signalling; that role alone does not predict a benefit.
Breadth
The relevant ingredient has a narrow mood-related role rather than several distinct supported benefits.

Evidence67

SAMe has possible benefits in depression-treatment contexts; everyday mood benefits in healthy adults remain unclear.
Evidence strength
SAMe has possible benefits in depression-treatment contexts; everyday mood benefits in healthy adults remain unclear.
Studied preparation
The declared ingredient identities are usable for comparison, but matching an ingredient does not guarantee the same mood effect.

Formulation logic100

The relevant ingredients have no missing required partner or identified internal conflict. This does not imply an added benefit from combining them.
Partner coverage
No required partner ingredient is missing for the relevant ingredients.
Conflicts
No particular conflict among these ingredients is identified.
Effective doses
The declared amount is within the included comparison range; this is not a minimum effective dose or a prediction of benefit.
Study evidence
SAMe Disputed 20 studies
Stress Relief
Stress Relief
Impact
High effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg

SAMe has an indirect connection to stress through its mood and metabolic roles. Those roles don't tell you whether taking it will make everyday pressures feel easier to manage. A direct stress-relieving effect remains unconfirmed, so the declared amount alone isn't a reliable guide to how much relief you might feel.

How this product is rated for Stress Relief

Ingredient fit75

SAMe relates indirectly through mood and metabolism rather than confirmed everyday stress relief.
Goal fit
SAMe relates indirectly through mood and metabolism rather than confirmed everyday stress relief.
Dose adequacy
Each serving supplies 400 mg SAMe, half the 800 mg central comparison reference; the comparison doesn't predict a stress-relieving effect.

Pathways17

SAMe's connection is confined to mood and metabolism, with direct stress relief unconfirmed.
Depth
SAMe's connection is confined to mood and metabolism, with direct stress relief unconfirmed.
Breadth
The indirect mood connection doesn't provide broad coverage of stress-related processes.

Evidence65

SAMe's mood and metabolic roles provide an indirect connection, with stress relief unconfirmed.
Evidence strength
SAMe's mood and metabolic roles provide an indirect connection, with stress relief unconfirmed.
Studied preparation
The relevant ingredient forms are compatible with their individual stress-related uses, subject to the benefit limits described here.

Formulation logic100

The relevant ingredients don't require an additional partner for their individual roles. No particular ingredient conflict is identified.
Partner coverage
The relevant ingredients can contribute individually without an additional required partner.
Conflicts
No particular conflict between the ingredients is identified.
Effective doses
Each serving supplies 400 mg SAMe, half the 800 mg central comparison reference; the comparison doesn't predict a stress-relieving effect.
Study evidence
SAMe Not classified

No linked studies yet.

Ingredients

IngredientAmount per servingScore
S-Adenosyl Methionine
400 mg 96
Gluten Free Adults 18–50 Vegan Dairy Free Women Vegetarian
Report overview
SAMe · 400 mg OverallScore96
A+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyB+ Value
It lists 400 mg of SAMe per serving and names the SAMe tosylate disulfate form. The label says the tablets are blister-packed and clearly identifies active SAMe; its cost per equivalent 400 mg amount is moderate.
How this ingredient is rated

Active Ingredient Quality & Bioavailability100

The label names SAMe tosylate disulfate and reports blister packaging, which helps limit moisture exposure.
Stabilized Salt Form
The label names SAMe tosylate disulfate, but doesn't clarify how much of the preparation uses that form.
Packaging Integrity
The label says the tablets are blister-packed, which helps protect them from moisture exposure.

Dose, Safety & Label Transparency100

The label clearly identifies the active SAMe amount and lists 400 mg per serving.
Active Dosage Strength
The serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The label clearly identifies the active SAMe amount.

Value80

The cost for an equivalent 400 mg amount is moderate.
Price Per 400mg Active Dose
The cost per equivalent 400 mg amount is moderate.
View ingredientView products
Loading alternative details
85 Performance

SAMe 400 mg

Lake Avenue Nutrition

A stabilized salt and enteric coating protect a full SAMe amount during storage and passage through the stomach. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Net active yield and moisture-resistant packaging remain unclear.

84 Performance

SAMe 400 mg

Life Extension

Enteric coating protects a full SAMe amount from stomach acid and supports purposeful delivery. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. The stabilized salt, net active yield, and moisture protection are not identified.

84 Performance

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt supplies a full SAMe amount in one tablet. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Enteric and sealed moisture protection are not stated, and net active yield remains unclear.

74 Budget

SAMe 200

Jarrow Formulas

A common starting SAMe amount provides a simple, low-cost option. It lowers routine cost versus the original. Neither a stabilized salt nor acid-resistant delivery is identified, so protected active yield is uncertain.

83 Budget

SAMe 200 mg

NOW

A stabilized disulfate tosylate salt provides a credible common starting amount at efficient routine value. It lowers routine cost versus the original. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

84 Budget

SAMe 400 mg

Nutricost

A stabilized salt provides a full SAMe amount with efficient dose value. It lowers routine cost versus the original. The two-capsule serving has no stated acid resistance, and moisture protection is unclear.

84 Value

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt provides a full SAMe amount with favorable dose value. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection and sealed moisture protection are not stated.

80 Value

SAMe 400 mg

Swanson

A stable disulfate tosylate form provides a full SAMe amount in one tablet. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

78 Value

SAMe 200 mg S-Adenosyl-Methionine

Life Extension

Enteric coating protects a common starting SAMe amount from stomach acid. Compared with the original, its delivery design and routine economics offer a useful value trade-off. The salt form, net active yield, and moisture protection are not identified.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis.
    Limveeraprajak N; Nakhawatchana S; Visukamol A; Siripakkaphant C; Suttajit S; Srisurapanont M · Progress in neuro-psychopharmacology & biological psychiatry · 2024
    Meta-analysis2,183 participants23 studies pooledMood Support forSAMe
  2. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis.
    Peng TR; Cheng HY; Wu TW · General hospital psychiatry · 2024
    Meta-analysis1,522 participants14 studies pooledMood Support forSAMe
  3. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
    Delle Chiaie R; Pancheri P; Scapicchio P · The American journal of clinical nutrition · 2002
    Randomized trial576 participantsMood Support forSAMe
  4. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
    Sarris J; Murphy J; Mischoulon D; Papakostas GI; Fava M; Berk M; Ng CH · The American journal of psychiatry · 2017
    Meta-analysisMood Support forSAMe
  5. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review.
    Williams AL; Girard C; Jui D; Sabina A; Katz DL · Clinical and investigative medicine. Medecine clinique et experimentale · 2005
    Meta-analysisMood Support forSAMe
  6. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
    Caruso I; Pietrogrande V · The American journal of medicine · 1988
    Clinical trial734 participantsJoint Health forSAMe
  7. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
    Najm WI; Reinsch S; Hoehler F; Tobis JS; Harvey PW · BMC musculoskeletal disorders · 2004
    Randomized trial61 participantsJoint Health forSAMe
  8. S-Adenosylmethionine for osteoarthritis of the knee or hip.
    Rutjes AW; Nüesch E; Reichenbach S; Jüni P · The Cochrane database of systematic reviews · 2010
    Meta-analysis656 participants4 studies pooledJoint Health forSAMe
  9. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis.
    Soeken KL; Lee WL; Bausell RB; Agelli M; Berman BM · The Journal of family practice · 2002
    Meta-analysis11 studies pooledJoint Health forSAMe
  10. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
    König B · The American journal of medicine · 1988
    Single-arm trial108 participantsJoint Health forSAMe
  11. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis.
    Domljan Z; Vrhovac B; Dürrigl T; Pucar I · International journal of clinical pharmacology, therapy, and toxicology · 1989
    Non-randomized trial20 participantsJoint Health forSAMe
  12. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledDetoxification forSAMe
  13. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledDetoxification forSAMe
  14. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.
    Medici V; Virata MC; Peerson JM; Stabler SP; French SW; Gregory JF; Albanese A; Bowlus CL; Devaraj S; Panacek EA; Richards JR; Halsted CH · Alcoholism, clinical and experimental research · 2012
    Randomized trial37 participantsDetoxification forSAMe
  15. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease.
    Ivashkin VT; Maevskaya MV; Kobalava ZD; Uspenskiy YP; Fominih JA; Rozanov AV; Tolkacheva VV; Sotnikova TI; Alikhanov BA; Gorbacheva IA; Ershova OB; Znakhyrenko AA; Sokolov KA; Sander-Struckmeier S · Minerva gastroenterologica e dietologica · 2019
    Single-arm trial72 participantsDetoxification forSAMe
  16. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsDetoxification forSAMe
  17. Beneficial effects of S-adenosyl-L-methionine on post-hepatectomy residual liver function: a prospective, randomized, controlled clinical trial.
    Su ZR; Cui ZL; Ma JL; Li JS; Ge YS; Yu JH; Pan JH; Xu GL; Jia WD · Hepato-gastroenterology · 2014
    Randomized trial79 participantsDetoxification forSAMe
  18. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsDetoxification forSAMe
  19. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsDetoxification forSAMe
  20. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
    Glorioso S; Todesco S; Mazzi A; Marcolongo R; Giordano M; Colombo B; Cherie-Ligniere G; Mattara L; Leardini G; Passeri M · International journal of clinical pharmacology research · 1985
    Randomized trial150 participantsJoint Health forSAMe
  21. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
    Hosea Blewett HJ · Critical reviews in food science and nutrition · 2008
    Narrative reviewJoint Health forSAMe
  22. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD · The international journal of neuropsychopharmacology · 2004
    Randomized trial293 participantsMood Support forSAMe
  23. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
    Di Pierro F; Settembre R · International journal of general medicine · 2015
    Randomized trial64 participantsMood Support forSAMe
  24. S-adenosylmethionine blood levels in major depression: changes with drug treatment.
    Bell KM; Potkin SG; Carreon D; Plon L · Acta neurologica Scandinavica. Supplementum · 1994
    Randomized trial26 participantsMood Support forSAMe